Literature DB >> 15254595

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

David H Munn1, Madhav D Sharma, Deyan Hou, Babak Baban, Jeffrey R Lee, Scott J Antonia, Jane L Messina, Phillip Chandler, Pandelakis A Koni, Andrew L Mellor.   

Abstract

One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs. We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO). Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs. Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs. Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice. Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19. We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254595      PMCID: PMC449750          DOI: 10.1172/JCI21583

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  82 in total

Review 1.  Tolerogenic dendritic cells.

Authors:  Ralph M Steinman; Daniel Hawiger; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 2.  Tolerance, DCs and tryptophan: much ado about IDO.

Authors:  Ursula Grohmann; Francesca Fallarino; Paolo Puccetti
Journal:  Trends Immunol       Date:  2003-05       Impact factor: 16.687

Review 3.  Dendritic cells in immunity and tolerance-do they display opposite functions?

Authors:  Muriel Moser
Journal:  Immunity       Date:  2003-07       Impact factor: 31.745

Review 4.  Tryptophan catabolism and regulation of adaptive immunity.

Authors:  Andrew L Mellor; David H Munn
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

5.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.

Authors:  Michael T Spiotto; Ping Yu; Donald A Rowley; Michael I Nishimura; Stephen C Meredith; Thomas F Gajewski; Yang Xin Fu; Hans Schreiber
Journal:  Immunity       Date:  2002-12       Impact factor: 31.745

6.  Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor.

Authors:  Li Yang; Noboru Yamagata; Rajwardhan Yadav; Suzanne Brandon; Regina L Courtney; Jason D Morrow; Yu Shyr; Mark Boothby; Sebastian Joyce; David P Carbone; Richard M Breyer
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

7.  The lymphoid past of mouse plasmacytoid cells and thymic dendritic cells.

Authors:  Lynn Corcoran; Isabel Ferrero; David Vremec; Karen Lucas; Jason Waithman; Meredith O'Keeffe; Li Wu; Anne Wilson; Ken Shortman
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

8.  Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice.

Authors:  Gregory J Gurtner; Rodney D Newberry; Suzanne R Schloemann; Keely G McDonald; William F Stenson
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

9.  Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.

Authors:  Ping Yu; Michael T Spiotto; Youjin Lee; Hans Schreiber; Yang-Xin Fu
Journal:  J Exp Med       Date:  2003-04-14       Impact factor: 14.307

10.  A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice.

Authors:  Ursula Grohmann; Francesca Fallarino; Roberta Bianchi; Ciriana Orabona; Carmine Vacca; Maria C Fioretti; Paolo Puccetti
Journal:  J Exp Med       Date:  2003-06-30       Impact factor: 14.307

View more
  316 in total

Review 1.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

2.  Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.

Authors:  Richard Metz; James B Duhadaway; Sonja Rust; David H Munn; Alexander J Muller; Mario Mautino; George C Prendergast
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

3.  Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells.

Authors:  Latt Latt Aung; Andrew Brooks; Steven A Greenberg; Michael L Rosenberg; Suhayl Dhib-Jalbut; Konstantin E Balashov
Journal:  J Neuroimmunol       Date:  2012-06-09       Impact factor: 3.478

4.  Indoleamine 2,3-dioxygenase and regulatory dendritic cells contribute to the allograft protection induced by infusion of donor-specific splenic stromal cells.

Authors:  Li Liu; Lihua Duan; Min Gong; Hong Dai; Quan Gong; Fang Zheng; Zheng Tan; Congyi Wang; Feili Gong; Min Fang
Journal:  Cell Mol Immunol       Date:  2010-11-08       Impact factor: 11.530

5.  Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

Authors:  Rikke Baek Sørensen; Sine Reker Hadrup; Inge Marie Svane; Mads Christian Hjortsø; Per Thor Straten; Mads Hald Andersen
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

6.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Authors:  Madhav D Sharma; Babak Baban; Phillip Chandler; De-Yan Hou; Nagendra Singh; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 7.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Mouse pancreatic islets are resistant to indoleamine 2,3 dioxygenase-induced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function.

Authors:  Reza B Jalili; Farshad Forouzandeh; Alireza Moeenrezakhanlou; Gina R Rayat; Ray V Rajotte; Hasan Uludag; Aziz Ghahary
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

Review 9.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

Review 10.  The plasmacytoid dendritic cell as the Swiss army knife of the immune system: molecular regulation of its multifaceted functions.

Authors:  Julien J Karrich; Loes C M Jachimowski; Christel H Uittenbogaart; Bianca Blom
Journal:  J Immunol       Date:  2014-12-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.